If you’re a self-directed investor and you want to know when is the next earnings report for Kadmon Holdings, Inc. (NASDAQ:KDMN), then you can look to the company’s earnings calendar. Kadmon files earnings reports four times a year. The company recently reported that its REZUROCK tablets were added to the NCCN Guidelines for the evaluation of Graft-Versus-Host Disease.
The company’s quarterly report is expected to show a decline in year-over-year earnings on lower revenues. However, the actual results may vary, and the company may post better or worse results. As a result, investors should pay close attention to this report and earnings estimates. The company’s current Zacks Rank is #4 (Sell). This means that it is underperforms the market.